Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Weinstein

Showing results (401-410 of 611) with videos related to

Pageof 62
Sort By:
Neuroscience|July 13, 2015
Gray matter damage in multiple sclerosis: Impact on clinical symptomsCaspar E P van Munster, Laura E Jonkman, Henry C Weinstein, et al.
Journal of Medical Economics|September 14, 2013
Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analysesGregory Hill, Richard Barron, Kelly Fust, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|December 29, 2014
Practice variation in long-term secondary stroke prevention in The NetherlandsSander M van Schaik, Blanche S de Vries, Henry C Weinstein, et al.
Hospital Formulary|June 9, 1987
Application of decision analysis to drug selection for formulary additionJ J Kresel, H C Hutchings, D N MacKay, et al.
Journal of Medical Economics|February 9, 2010
Economic assessment of doripenem versus imipenem in the treatment of ventilator-associated pneumoniaLisa J McGarry, Sanjay Merchant, Dilip Nathwani, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|January 10, 2017
Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness modelsKelly Fust, Anju Parthan, Michael Maschio, et al.
Journal of General Internal Medicine|November 1, 1986
Cost-effective choice of antimicrobial therapy for serious infectionsM C Weinstein, J L Read, D N MacKay, et al.
International Journal of MS Care|July 20, 2023
Rest-Activity Rhythm, Pain, and Motor Activity in Multiple SclerosisRogier J Scherder, M J van Dorp, A J Prins, et al.
Journal of the American College of Cardiology|September 14, 1999
The relative influence of secondary versus primary prevention using the National Cholesterol Education Program Adult Treatment Panel II guidelinesL Goldman, P Coxson, M G Hunink, et al.
Medical Care|July 21, 1999
Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregiversP J Neumann, K M Kuntz, J Leon, et al.
Pageof 62

Showing results (401-410 of 611) with videos related to

Sort By:
Pageof 62
Neuroscience|July 13, 2015
Gray matter damage in multiple sclerosis: Impact on clinical symptomsCaspar E P van Munster, Laura E Jonkman, Henry C Weinstein, et al.
Journal of Medical Economics|September 14, 2013
Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analysesGregory Hill, Richard Barron, Kelly Fust, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|December 29, 2014
Practice variation in long-term secondary stroke prevention in The NetherlandsSander M van Schaik, Blanche S de Vries, Henry C Weinstein, et al.
Hospital Formulary|June 9, 1987
Application of decision analysis to drug selection for formulary additionJ J Kresel, H C Hutchings, D N MacKay, et al.
Journal of Medical Economics|February 9, 2010
Economic assessment of doripenem versus imipenem in the treatment of ventilator-associated pneumoniaLisa J McGarry, Sanjay Merchant, Dilip Nathwani, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|January 10, 2017
Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness modelsKelly Fust, Anju Parthan, Michael Maschio, et al.
Journal of General Internal Medicine|November 1, 1986
Cost-effective choice of antimicrobial therapy for serious infectionsM C Weinstein, J L Read, D N MacKay, et al.
International Journal of MS Care|July 20, 2023
Rest-Activity Rhythm, Pain, and Motor Activity in Multiple SclerosisRogier J Scherder, M J van Dorp, A J Prins, et al.
Journal of the American College of Cardiology|September 14, 1999
The relative influence of secondary versus primary prevention using the National Cholesterol Education Program Adult Treatment Panel II guidelinesL Goldman, P Coxson, M G Hunink, et al.
Medical Care|July 21, 1999
Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregiversP J Neumann, K M Kuntz, J Leon, et al.
Pageof 62